Hyaluronic Acid-enriched Transfer Medium in Single Blastocyst Transfer

Last updated: February 20, 2025
Sponsor: Northwest Women's and Children's Hospital, Xi'an, Shaanxi
Overall Status: Active - Recruiting

Phase

N/A

Condition

Infertility

Treatment

Low Hyaluronic Acid concentrations (0.125 mg/ml)

High Hyaluronic Acid concentrations (0.5 mg/ml)

Clinical Study ID

NCT06492785
2024-127
  • All Genders

Study Summary

The purpose of this study is to compare the live birth rates of high concentration of Hyaluronic Acid (0.5 mg/ml) transfer medium (EmbryoGlue®) to those containing low Hyaluronic Acid concentrations (0.125 mg/ml) (G2 medium) in women undergoing single fresh and frozen blastocyst transfer.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. All cycles with single blastocyst transfer will be considered eligible

  2. Both fresh and cryopreserved embryo transfer cycles utilizing autologous oocytes

  3. No age restriction will be applied

  4. Informed consent was signed

Exclusion

Exclusion Criteria:

  1. Uterine anatomic anomalies

  2. Women with untreated hydrosalpines

  3. Once couples have been enrolled in the trial, subsequent cycles will not beincorporated.

Study Design

Total Participants: 858
Treatment Group(s): 2
Primary Treatment: Low Hyaluronic Acid concentrations (0.125 mg/ml)
Phase:
Study Start date:
September 19, 2024
Estimated Completion Date:
September 30, 2026

Study Description

The single blastocyst-stage embryo transfer cycles will be randomised in a 1:1 allocation, with block sizes of 2 and 4 on the day of Embryo Transfer (ET). This randomisation process will be centrally managed via a web-based electronic data capture system and will be stratified according to the treatment center. The allocation sequence and the designated treatment will be completely concealed from the participating couples, clinicians - including those conducting the transfer procedures - and outcome assessors. Given the intrinsic viscous nature of EmbryoGlue, embryologists, who who are responsible for the procedures in the laboratory will not be subjected to blinding. Only at the end of the study, when data collection is completed, the allocation sequence will be revealed to the primary investigators.

Connect with a study center

  • IVF laboratory

    Xi'an, Shaanxi 710003
    China

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.